Phase 2 N=95 Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: Overall Survival — 8.55; 8.55 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=375 A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
Infections, Rotavirus · Rotavirus Vaccines
Primary: Number of Seroconverted Subjects for Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibody — 84 Subjects
Phase 2 N=62 Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
HER2-mutant Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 0; 6 Participants
Phase 2 N=50 Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Maximum Tolerated Dose of Clofarabine — 25 mg/m^2 of clofarabine
Phase 2 N=232 A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Percentage of Meibum Quality Responders in the Study Eye — 46.3; 33.9; 32.1; 42.9 Percentage of Patients
Phase 2 N=64 Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
Renal Anemia
Primary: Change in Average Hb Concentration Between Baseline and Evaluation Period — 11.26; 11.08; -0.78; -0.15 g/dL
Phase 2 N=18 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Phase 2 N=142 Treatment of Smoking Among Individuals With PTSD
Cigarette Smoking · Nicotine Dependence · Post-traumatic Stress Disorder
Primary: Number of Participants With 7-day Point Prevalence Smoking Abstinence — 8; 11 Participants
Phase 2 N=15 A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Ovarian Cancer
Primary: Part 2: Median Progression-free Survival (PFS) in Weeks Based on Enhanced Response Evaluation Criteria In Solid Tumors Version 1.1 (Enhanced RECIST 1.1) by Independent…
Phase 2 N=31 Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1 — 0; 1 participants
Phase 2 N=576 Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29 — 0.058; 0.088; 0.060; 0.073 Liter — p=0.009
Phase 2 N=16 Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid Dependence
Primary: Successful Naltrexone Initiation — 11 Participants
Phase 2 N=171 OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Stage IA Fallopian Tube Cancer · Stage IA Ovarian Cancer · Stage IB Fallopian Tube Cancer
Primary: Progression-free Survival (PFS) — 5.9; 6.5 Months
Phase 2 N=700 Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
Asthma
Primary: Mean Change From Baseline to the End of the 8-Week Treatment Period in Trough Forced Expiratory Volume in One Second (FEV1) — 0.12; 0.18; 0.23; 0.19 Liters — p=0.326
Phase 2 N=6 Nalrexone Facilitated Discontinuation of Buprenorphine
Stable Opioid Dependence
Primary: Successful Discontinuation of Buprenorphine — 6 Participants